• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Celyad Oncology

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

November 4, 2020 By Celyad Oncology

  • Three accepted abstracts will be presented virtually in a pre-recorded poster session

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually from December 5-8, 2020. The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02. In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood.

ASH 2020 Presentation Details:

The following abstracts published today are now available on the ASH conference website. Following their presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.

Publication #1428:            Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma

Session Name:                  703. Adoptive Immunotherapy: Poster I

Date:                                    Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT

Publication #993:              Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Session Name:                  613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Date:                                    Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT

Publication #990:              First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Session Name:                  613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Date:                                    Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT

About CYAD-211

CYAD-211 is an investigational, short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T cell receptor (TCR) complex. In July 2020, Celyad Oncology announced FDA Clearance of its IND application for CYAD-211.

About CYAD-01

CYAD-01 is an investigational CAR T therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells.

About CYAD-02

CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor (CAR), a receptor expressed on natural killer cells that binds to eight stress-induced ligands expressed on tumor cells, and (ii) short hairpin RNA (shRNA) SMARTvector technology licensed from Horizon Discovery to knockdown the expression of NKG2D ligands MICA and MICB on the CAR T cells. In preclinical models, shRNA-mediated knockdown of MICA and MICB expression on NKG2D CAR T cells has shown enhanced in vitro expansion, as well as enhanced in vivo engraftment and persistence, of the CAR T cells, as compared to first-generation NKG2D receptor based CAR T cells.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Celyad Oncology Announces November 2020 Investor Conference Schedule

November 2, 2020 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in November 2020:

Bryan, Garnier & Co. Virtual European Healthcare Conference

Date: Monday, November 16, 2020

Jefferies Virtual London Healthcare Conference

Date: Tuesday, November 17, 2020

Time: 2:55 p.m. ET / 8:55 p.m. CET

Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website

SVB Leerink Oncology 1×1 Day

Date: Thursday, November 19, 2020

Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Uncategorized

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

September 29, 2020 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today that the Company has entered into a clinical trial collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, through a subsidiary.

Celyad Oncology will conduct the Phase 1b KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology’s investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy, with MSD’s anti-­PD-­1 therapy, KEYTRUDA® (pembrolizumab) in refractory metastatic colorectal cancer (mCRC) patients with microsatellite stable (MSS) / mismatch-repair proficient (pMMR) disease.

“We are extremely pleased to enter into this clinical collaboration with MSD, as we believe the mechanism of actions of CYAD-101 and KEYTRUDA are highly complementary and could help to drive meaningful clinical benefit in patients with advanced metastatic colorectal cancer, in particular with microsatellite stable disease where a high unmet medical need exists” said Filippo Petti, Chief Executive Officer of Celyad Oncology. “In addition, the collaboration with MSD adds an important dimension to our clinical program for CYAD-101 for the treatment of mCRC and provides us with the opportunity to build upon the encouraging clinical activity we’ve reported to date from the ongoing alloSHRINK trial.”

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About CYAD-101

CYAD-101 is an investigational, non-gene edited, allogeneic (healthy donor derived) CAR T candidate engineered to co-express a chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands and the novel inhibitory peptide TIM (TCR Inhibitory Molecule). The expression of TIM reduces signaling of the TCR complex, which is responsible for graft-versus host disease.

Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Uncategorized

Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit

September 23, 2020 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Filippo Petti, Chief Executive Officer, will participate in a fireside chat at the virtual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 11:00 a.m. EDT.

The live virtual event will be available for investors to listen to via a webcast made available on the Celyad Oncology website. An archived replay of the event will be available on the Company’s website for approximately 30 days.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Celyad Oncology to Host Virtual Research & Development Webinar on September 29, 2020

September 22, 2020 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, September 29th at 11:00 a.m. EDT.

The program will provide insights into the company’s novel, non-gene edited allogeneic CAR T candidates CYAD-101 for metastatic colorectal cancer and CYAD-211 for relapsed / refractory multiple myeloma as well as the company’s short hairpin RNA (shRNA) platform and all-in-one vector approach. The featured speaker, Dr. Richard Kim, M.D., Professor of Oncology, Moffitt Cancer Center, will discuss the immuno-oncology and treatment landscapes for metastatic colorectal cancer. Members of Celyad Oncology’s management will highlight recent developments in the company’s pipeline and discuss the future direction for additional next-generation, allogeneic CAR T candidates.

The live webcast of the presentation can be accessed by visiting the “Events” section of the Celyad Oncology website.  Please connect to the webcast several minutes prior to the start of the event to ensure the connection. To register for the live webcast, click here.  After the conclusion of event, a replay of the webcast will also be available on the Celyad Oncology website.  

Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Uncategorized

Celyad Oncology Establishes At-the-Market Facility

September 14, 2020 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into an Open Market Sale AgreementSM with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, for a period of up to 36 months, through “an at the market offering” (“ATM”), with Jefferies acting as sales agent, up to $25,000,000 of new American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company, assuming sales of 2,522,704 ADSs in the offering at an offering price of $9.91 per ADS, which was the last reported sale price of the ADSs on the Nasdaq Global Market on September 8, 2020 . The actual number of ADSs issued will vary depending on the sales prices under this offering, however the number of ordinary shares shall not exceed 2,777,777 shares. The new ADSs will be sold at then current market prices. Sales of ADSs in the ATM will only be conducted in the United States through the Nasdaq Stock Market or any other existing U.S. trading market for the ADSs. No sales of ADSs will be conducted in Belgium or through Euronext.

Celyad Oncology currently intends to use net proceeds from sales of ADSs in the ATM for general corporate purposes, including but not limited to the research and development of Company’s clinical and preclinical CAR T cell therapy candidates.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

The securities are being offered pursuant to a shelf registration statement on Form F-3 (333-248464), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 4, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A prospectus supplement relating to the offering was filed by Celyad Oncology with the SEC on September 11, 2020 and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-547-6340 or by email at Prospectus_Department@Jefferies.com.

Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Uncategorized Tagged With: regulated information

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy